With a broad search strategy and large sample size, this meta-analysis comprehensively analyzed the discriminatory diagnostic ability of a HER2-enriched subtype and the presence of PIK3CA mutations and TILs, HRs, and Ki-67 in predicting pCR to neoadjuvant therapy in patients with HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.